Every 424B that Microvision (MVIS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MVIS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MVIS filings page.
MicroVision, Inc. is conducting a primary offering of 6,800,000 shares of common stock together with 6,800,000 Common Warrants, with each share sold with one warrant at a combined public offering price of $2.50. The warrants are immediately exercisable at $2.50 per share and expire five years after issuance. Gross proceeds are expected to be $17.0 million, with estimated net proceeds of approximately $15.6 million after placement fees and expenses, excluding any proceeds from warrant exercises. Shares outstanding will increase from 23,350,027 to 30,150,027 after the offering, before any warrant exercise. MicroVision plans to use the net proceeds for general corporate purposes, including working capital and capital expenditures.
MicroVision, Inc. is conducting a primary offering of common stock, Pre-Funded Warrants and five-year Common Warrants under its $50,000,000 shelf registration. Each share of common stock (or Pre-Funded Warrant) is sold together with one Common Warrant, with the mix between shares and Pre-Funded Warrants driven by beneficial ownership limits of 4.99% or 9.99% of outstanding stock. The deal is a best-efforts placement through WestPark Capital, which will receive a 6.5% cash fee on gross proceeds and expense reimbursement, and there is no minimum amount required to close. MicroVision plans to use net proceeds for general corporate purposes, including working capital and capital expenditures. The company recently effected a 1-for-15 reverse stock split and reduced authorized common stock to 150,000,000 shares, and has a history of operating losses funded largely through equity and convertible securities. The filing highlights potential dilution, stock-price volatility, lack of a trading market for the Warrants and the absence of any current dividend policy.
MicroVision, Inc. proposes to register up to $42,000,000 of common stock for sale under an at-the-market program. The prospectus states sales may be made from time to time through Deutsche Bank Securities, Mizuho Securities USA and Craig-Hallum, acting as agents or principals, under a Sales Agreement amended June 12, 2026.
The filing illustrates an example that assumes issuance of 116,666,666 shares at an assumed price of $0.36 per share, which would result in up to 461,312,631 shares outstanding (based on 344,645,965 shares outstanding as of May 28, 2026). Net proceeds are intended for general corporate purposes.
MicroVision, Inc. registers for resale up to 61,315,970 shares of common stock issuable upon conversion of senior secured convertible notes due 2028. The shares are being registered for the selling stockholders; the company will not receive any proceeds from resales. The registration reflects Convertible Notes with an initial conversion price of $0.8819 per share and an aggregate principal amount of approximately $43 million. The prospectus discloses 326,982,727 shares outstanding as of April 20, 2026 and states a post-offering hypothetical outstanding share count of 388,298,697 if all Shares are issued. The Convertible Notes include a 4.99% beneficial ownership limitation (increaseable to 9.99% with notice), optional monthly partial redemptions, a Forced Conversion trigger tied to a sustained VWAP > $2.00, and secured, senior ranking collateral. This prospectus covers resale mechanics, permitted sale methods, and customary plan-of-distribution language.